Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring
From obesity to cancer, investors will do well to watch these 6 clinical trials.
23 hours ago - Barrons
AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m.
4 days ago - PRNewsWire
AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m.
5 days ago - PRNewsWire
Final Trades: Intuit, Amgen, the INDY and URNM
The Investment Committee give you their top stocks to watch for the second half.
Other symbols: INTUINDYURNM
6 days ago - CNBC Television
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders ...
Other symbols: CRBPGPCRSRRKVKTX
8 days ago - Market Watch
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS
First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. , Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (a...
14 days ago - PRNewsWire
3 ‘Recession-Resistant' Dividends Growing Up To 12% Annually
Let's talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one. Here at Contrarian Outlook we have been preparing...
Other symbols: ABTUNH
19 days ago - Forbes
Amgen Stock Slides on Lowered Guidance
Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance.
27 days ago - Investopedia
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
BMO Capital Markets writes, “A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in obesity and inflammatory disease.” The analyst keeps the Outperform ra...
27 days ago - Benzinga
Amgen CFO talks Q2 earnings, obesity drug, and growth
Amgen (AMGN) posted second quarter revenue of $8.4 billion, topping expectations of $8.34 billion. Sales rose by 20% in the quarter, however, the company noted that lower net selling prices partially ...
4 weeks ago - Yahoo Finance
Amgen second quarter profit dips, sales rise 20%
Amgen on Tuesday said its second-quarter profit slipped 1% as higher expenses offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horiz...
4 weeks ago - Reuters
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024.
4 weeks ago - PRNewsWire
Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Amgen Inc. AMGN is expected to release earnings results for its second quarter, after the closing bell on Tuesday, Aug. 6.
4 weeks ago - Benzinga
Investing in biotech outside of weight-loss drugs
GLP-1 weight-loss drugs have pushed the biotech sector to new heights as demand steadily increases. But despite the drugs' popularity, there are other investment opportunities within the biotech secto...
Other symbols: VRTX
4 weeks ago - Yahoo Finance
AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024.
4 weeks ago - PRNewsWire
AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Aug. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of th...
4 weeks ago - PRNewsWire
Pharma companies less concerned after hearing from US on negotiated prices for Medicare
Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential su...
Other symbols: ABBVAZNBMYJNJ
5 weeks ago - Reuters
Trade Tracker: Kevin Simpson sells Cisco and buys more TJX Companies and Amgen
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest trades.
Other symbols: CSCOTJX
7 weeks ago - CNBC Television
‘Crash proof' your portfolio with these 10 stocks and 3 ETFs
You don't get upset for having homeowner's insurance but your house doesn't burn down. The same principle should apply to investors who insure their stock portfolios against a crash.
Other symbols: CAHFIGLHEGDJPMMRKOKE
2 months ago - Market Watch
Weighing the Future of Weight Loss Drugs
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
Other symbols: LLYNVOPFE
2 months ago - Schwab Network
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
Other symbols: AZNLLYMRKNVO
2 months ago - Yahoo Finance
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Other symbols: BMYIONSXBI
2 months ago - Barrons
PLTR, AMGN, LMT: Must Watch Stocks
Palantir (PLTR) shares are trading between the $20 to $25 range. Amgen (AMGN) is coming out of the GLP-1 Phase 3 trial with a once a month delivery versus once a week.
Other symbols: PLTRLMT
2 months ago - Schwab Network
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy Alone First and Only Bispecific T-cell Engager (BiTE ®) ...
2 months ago - PRNewsWire
A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL
The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to signif...
Other symbols: LLYCRLTMO
2 months ago - Schwab Network
